VPTDF - Ventripoint Heart Analysis System to be used at the Stollery Children's Hospital to Study Atrial Dysfunction in Children
(TheNewswire)
Toronto, Ontario – TheNewswire –February 23, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is announcing thecommencement of a new clinical study to measure atrial volumes andejection fractions in children with suspected valvular disease. Thestudy is being conducted by cardiologists in the Department ofPediatrics, Division of Pediatric Cardiology at the University ofAlberta in collaboration with the Mazankowski Heart Institute andStollery Children’s Hospital.
There is a real need for a reliable, accurate andsimple procedure to assess valvular function especially between theatria and ventricles of the heart. Left atrial enlargement is anindicator of diastolic dysfunction due to congenital or acquired leftheart disease, volume overload due to left to right shunting, a markerof severity of mitral stenosis and regurgitation, and a risk factorfor atrial arrhythmias. Right atrial volume is a known marker forright ventricular diastolic dysfunction and severity of tricuspidregurgitation or stenosis. The VMS+3.0 is uniquely able to measurevolumes for all 4 chambers of the heart using 2D ultrasound and so canprovide regular monitoring of children throughout their early years asthe heart grows. This information is critical to determine the needand timing for therapeutic interventions.
“Ventripoint is pleased to sponsor this study tofurther show how repeated rapid assessment paediatric patients using2D ultrasound can assist in therapeutic decisions,” stated Dr.George Adams, Executive-Chairman of Ventripoint. “3Dechocardiography is often unreadable and MRI procedures are tooexpensive and arduous to perform frequently as the child grows.
This study aims to demonstrate the capabilities of theVMS+3.0 in assessing the performance and function of the left andright atria in combination with the ventricle assessment. Forcomparison purposes, the children will also be assessed by 3Dultrasound, as well as MRI, when possible.
About Stollery Children’sHospital
The Stollery Children’s Hospital is located inEdmonton, Alberta. The hospital is comprised of 232 beds, whichinclude inpatient and critical care beds. Over 50% of their beds arecritical care beds. The Stollery Children’s Hospital providequaternary services to Alberta and Western Canada for some of thehighly specialized services. Flagship programs include the cardiac andtransplant services.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.